Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

788
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
788
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

631
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

942
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
942
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

750
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
750
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

886
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
886

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracardiac Electrograms During Left Bundle Branch Area Pacing Implantation.

JACC. Clinical electrophysiology·2026
Same author

Predictors of pacing-induced cardiomyopathy in patients undergoing AV nodal ablation: insights from a Delphi process and retrospective cohort study.

European heart journal open·2026
Same author

Bridging the gap: adapting heart failure guidelines for resource-limited settings: A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2026
Same author

Conduction System Pacing With AV Node Ablation Versus Pulmonary Vein Isolation: Emerging Evidence.

JACC. Asia·2026
Same author

Safety and performance of a novel ICD lead for left bundle branch area pacing: Results from the ASCEND CSP trial.

Heart rhythm·2026
Same author

Left Bundle Branch Area Pacing: Does Lead Position Matter?

JACC. Clinical electrophysiology·2026

Related Experiment Video

Updated: Apr 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

[Update on indications for cardiac resynchronization therapy].

Sara Schukraft, Haran Burri

    Revue Medicale Suisse
    |June 27, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Cardiac resynchronization therapy (CRT) guidelines now include QRS morphology for better patient selection. Updated European Society of Cardiology recommendations expand CRT use in heart failure patients needing ventricular pacing.

    More Related Videos

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    2.3K
    Implantation of Total Artificial Heart in Congenital Heart Disease
    07:27

    Implantation of Total Artificial Heart in Congenital Heart Disease

    Published on: July 18, 2014

    28.4K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
    12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    10.2K
    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
    10:17

    Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

    Published on: April 11, 2025

    2.3K
    Implantation of Total Artificial Heart in Congenital Heart Disease
    07:27

    Implantation of Total Artificial Heart in Congenital Heart Disease

    Published on: July 18, 2014

    28.4K

    Area of Science:

    • Cardiology
    • Medical Device Therapy

    Background:

    • Cardiac resynchronization therapy (CRT) is established for systolic heart failure (NYHA class II-IV, ejection fraction ≤35%, QRS duration ≥120 ms).
    • European Society of Cardiology (ESC) pacemaker guidelines were updated in 2013.

    Purpose of the Study:

    • To review and comment on the 2013 ESC pacemaker guidelines.
    • To highlight key changes in patient selection and prescription criteria for CRT.

    Main Methods:

    • Review of the 2013 European Society of Cardiology pacemaker guidelines.
    • Analysis of updated recommendations for cardiac resynchronization therapy.

    Main Results:

    • Guideline updates incorporate QRS morphology for optimizing CRT patient selection.
    • CRT is now recommended for patients with reduced ejection fraction requiring frequent ventricular pacing, regardless of baseline QRS duration or heart failure status.

    Conclusions:

    • The 2013 ESC guidelines refine CRT indications, emphasizing QRS morphology and broader application in specific heart failure patient groups.
    • These updates aim to improve treatment outcomes for patients with heart failure and conduction abnormalities.